Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
Last trade$1.34
Day change-$0.065 (-4.63%)
Day range$1.29 – $1.39
Volume55,612
Market cap$157M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for IPHA.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for IPHA.
Recent news
Company coverage with links to the original publishers.
Innate Pharma (IPHA) has declined 25% over four weeks but shows signs of oversold conditions with an RSI reading of 29.75. Analysts have raised earnings estimates by 32.9% over the past 30 days, and the stock holds a Zacks Rank #2 (Buy) rating, suggesting a potential near-term turnaround.
GT Biopharma announced its third cancer drug, GTB-5550, entered Phase 1 clinical trials on May 14, 2026, marking the company's first expansion into solid tumors. Despite having three drugs in human trials—unusual for a micro-cap—the company trades at a significant valuation discount compared to peers, with only ~$9 million in cash and a runway into late 2026. The gap between its scientific promise and market valuation presents both opportunity and substantial risk, with near-term catalysts including clinical data updates and financing announcements expected in H2 2026.
Over 30 pharmaceutical companies are actively developing more than 30 pipeline drugs for cutaneous T-cell lymphoma (CTCL), a rare non-Hodgkin lymphoma affecting the skin. Key players including Prescient Therapeutics, Innate Pharma, and others are advancing promising therapies with various mechanisms of action through clinical trials. The market is projected to grow steadily driven by increasing adoption of targeted and immunotherapies, though limited patient populations and high treatment costs remain challenges.
The peripheral T-cell lymphoma (PTCL) treatment market is projected to grow at a 7% CAGR through 2036, driven by increasing disease incidence and expanding patient populations. The market was valued at USD 800 million in 2025, with the US accounting for 68% of the market. Multiple emerging therapies from major pharmaceutical companies are expected to transform the treatment landscape, with ADCETRIS currently holding the largest market share at over USD 300 million.
Coherus Oncology announced the appointment of Arvind Sood as Chief Strategy and Corporate Affairs Officer, focusing on advancing innovative cancer therapeutics and driving revenues for LOQTORZI®.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.